Researchers who tested the vaccine in a combined Phase 1-2 trial — mostly meant to show safety — found either one or two doses of the vaccine generated both antibody and T-cell responses against the coronavirus. The trials were not…
Researchers who tested the vaccine in a combined Phase 1-2 trial — mostly meant to show safety — found either one or two doses of the vaccine generated both antibody and T-cell responses against the coronavirus. The trials were not…
NBC News medical contributor Dr. Natalie Azar talks on TODAY about the latest coronavirus headlines, including a new strain of the virus that’s being reported in the UK and elsewhere. “At the moment, experts are saying that it’s unlikely that…
NBC News medical contributor Dr. Vin Gupta and CNBC’s senior health and science reporter Meg Tirrell join TODAY to discuss the latest news surrounding coronavirus vaccine candidates. They discuss the possibility of a vaccine passport required by businesses and events…